Bristol-myers Squibb Compnay

Other

Pamela A Trail

David Willner

Gary R Braslawsky

Sandra J Hofstead

Robert S Greenfield

H Dalton King

Raymond A Firestone

Dalton King

Richard Wei-Dong Ji

Mohammad Eghtedarzadeh Kondri

Richard-Weidong Ji

The present invention concerns peptide fragments of angiostatin containing lysine-binding sites of angiostatin which can be used as anti-angiogenic agents for the treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerotic plaque formation, and any disease process that involves angiogenesis. The lysine binding fragments are derived from kringles 1,2 and/or 4 of plasminogen.

Lysine binding fragments of angiostatin

Branched hydrazone linkers for linking a targeting ligand such as an antibody to a therapeutically active drug. The point of branching is at a polyvalent atom and the number of drugs increases by a factor of two for each generation of branching. A preferred drug is doxorubicin.

Branched hydrazone linkers

The present invention relates to compositions that inhibit the proliferation and migration of endothelial cells. The compositions contain a pre-activation domain (&ldquo;PAD&rdquo;) from plasminogen, or a biologically active fragment thereof, and at least one kringle region from plasminogen, or a biologically active portion thereof. The compositions are useful to treat angiogenic associated disorders.

Anti-angiogenic agent and method for inhibiting angiogenesis

Provided are drug/ligand compounds of Formula (I): ##STR1## (I) in which

Thioether conjugates

Provided are drug/ligand compounds of Formula (I): ##STR1## in which D is a drug moiety;

Growing community of inventors

Yardley, PA, United States of America

Pamela A Trail